Your browser doesn't support javascript.
Early use of tocilizumab in solid organ transplant recipients with COVID-19: A retrospective cohort study in Saudi Arabia.
Yamani, Amani H; Alraddadi, Basem M; Almaghrabi, Reem S; Amer, Afnan A; Mehdawi, Fatimah S; Al-Hamzi, Mohammed A; Aldajani, Meshari S; Alattas, Majda S; Elsaed Ramadan, Aiman M; Wali, Ghassan Y; Alshukairi, Abeer N; Al Mutair, Abbas.
  • Yamani AH; Department of Medicine, Division of Infectious Diseases, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
  • Alraddadi BM; Department of Medicine, Division of Infectious Diseases, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
  • Almaghrabi RS; Department of Medicine, Division of Infectious Diseases, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Amer AA; Department of Medicine, Division of Infectious Diseases, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
  • Mehdawi FS; Infectious Diseases Department, Fakeeh Care, Jeddah, Saudi Arabia.
  • Al-Hamzi MA; Department of Medicine, Division of Infectious Diseases, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
  • Aldajani MS; Department of Medicine, Division of Infectious Diseases, King Abdulaziz Specialist Hospital, Taif, Saudi Arabia.
  • Alattas MS; Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
  • Elsaed Ramadan AM; Infection Control Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • Wali GY; Department of Medicine, Division of Infectious Diseases, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
  • Alshukairi AN; Department of Medicine, Division of Infectious Diseases, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
  • Al Mutair A; College of Medicine, AlFaisal University, Riyadh, Saudi Arabia.
Immun Inflamm Dis ; 10(3): e587, 2022 03.
Article in English | MEDLINE | ID: covidwho-1625924
ABSTRACT

BACKGROUND:

Tocilizumab was studied to reduce cytokine syndrome in patients with severe COVID-19 pneumonia in solid organ transplant (SOT) recipients with conflicting results. We aim to study the early use of tocilizumab in SOT with COVID-19 pneumonia on low flow oxygen.

METHODS:

This is a retrospective cohort study that was conducted in two transplant centers in Saudi Arabia among 46 SOT with COVID-19 comparing 21 patients who received tocilizumab to 25 patients who received standard of care. Their clinical characteristics and outcomes were described.

RESULTS:

Compared to patients who received standard of care, patients in the tocilizumab group were older (60.2 ± 12.8 vs. 48.6 ± 12.3, p = .003), had higher ferritin (862.1 ± 919.1 vs. 414 ± 447.3, p = .025) and C-reactive protein (CRP) (85 ± 83.1 vs. 42.9 ± 57.3, p = .012). More patients in the tocilizumab group required high flow oxygen (38.1% vs. 8.0%, p = .028) compared to patients on standard of care. There were no differences in mortality or mechanical ventilation requirement. Hospital stay was significantly shorter in the tocilizumab group than the standard of care group (9.6 ± 7.4 vs. 20.7 ± 11.7, p < .001).

CONCLUSIONS:

Early use of tocilizumab in SOT was associated with a shorter hospital stay. There was no difference in mortality rate and the requirement for mechanical ventilation in both groups.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Organ Transplantation / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Asia Language: English Journal: Immun Inflamm Dis Year: 2022 Document Type: Article Affiliation country: Iid3.587

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Organ Transplantation / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Asia Language: English Journal: Immun Inflamm Dis Year: 2022 Document Type: Article Affiliation country: Iid3.587